ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency

12 11 2021 07:22:40 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results

10 11 2021 16:01:02 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021

09 11 2021 08:00:05 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S - Share Repurchase Program Update

08 11 2021 08:00:03 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10

03 11 2021 08:00:02 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

15 10 2021 08:00:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting

30 9 2021 16:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Share Repurchase Program

29 9 2021 16:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

22 9 2021 16:27:29 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Upcoming Investor Presentations

07 9 2021 17:09:33 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

07 9 2021 16:59:54 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

01 9 2021 19:43:47 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

31 8 2021 16:01:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

25 8 2021 16:12:26 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

25 8 2021 15:24:38 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

17 8 2021 16:17:20 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

06 8 2021 07:05:00 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update

06 7 2021 08:00:01 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

11 6 2021 17:57:46 提供 Nasdaq GlobeNewswire

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

28 5 2021 07:05:00 提供 Nasdaq GlobeNewswire